Bulletin 25 | Nicola Oliver
An effective vaccine will ultimately allow life to return to normal, but the development process is lengthy and success is not guaranteed. In this bulletin we present an overview of potential vaccine candidates. We also discuss other pharmaceutical approaches, such as antiviral drugs.
At the time of writing, there are around nine clinical trials in humans in progress to test a potential vaccine against SARS-CoV-2 in phases 1 and 2. The overall ‘from phase 1 to approval’ success rate is no more than 15%. There are, however, many antiviral drug trials at the more advanced phase 3. Cautious optimism is the key here.